Comparison  ||| S:0 E:11 ||| NN
of  ||| S:11 E:14 ||| IN
two  ||| S:14 E:18 ||| CD
botulinum  ||| S:18 E:28 ||| JJ
toxin  ||| S:28 E:34 ||| NN
type  ||| S:34 E:39 ||| NN
A  ||| S:39 E:41 ||| DT
preparations  ||| S:41 E:54 ||| NN
for  ||| S:54 E:58 ||| IN
treating  ||| S:58 E:67 ||| VBG
crow ||| S:67 E:71 ||| NN
's  ||| S:71 E:74 ||| POS
feet ||| S:74 E:78 ||| NNS
:  ||| S:78 E:80 ||| :
a  ||| S:80 E:82 ||| DT
split-face ||| S:82 E:92 ||| JJ
,  ||| S:92 E:94 ||| ,
double-blind ||| S:94 E:106 ||| NNP
,  ||| S:106 E:108 ||| ,
proof-of-concept  ||| S:108 E:125 ||| JJ
study  ||| S:125 E:131 ||| NN
This  ||| S:131 E:136 ||| DT
is  ||| S:136 E:139 ||| VBZ
the  ||| S:139 E:143 ||| DT
first  ||| S:143 E:149 ||| JJ
double-blind ||| S:149 E:161 ||| NN
,  ||| S:161 E:163 ||| ,
randomized ||| S:163 E:173 ||| NN
,  ||| S:173 E:175 ||| ,
proof-of-concept  ||| S:175 E:192 ||| JJ
study  ||| S:192 E:198 ||| NN
to  ||| S:198 E:201 ||| TO
compare  ||| S:201 E:209 ||| VB
the  ||| S:209 E:213 ||| DT
clinical  ||| S:213 E:222 ||| JJ
effectiveness  ||| S:222 E:236 ||| NN
of  ||| S:236 E:239 ||| IN
botulinum  ||| S:239 E:249 ||| JJ
toxin  ||| S:249 E:255 ||| NN
type  ||| S:255 E:260 ||| NN
A  ||| S:260 E:262 ||| DT
( ||| S:262 E:263 ||| -LRB-
BoNTA ||| S:263 E:268 ||| NNP
)  ||| S:268 E:270 ||| -RRB-
free  ||| S:270 E:275 ||| JJ
of  ||| S:275 E:278 ||| IN
complexing  ||| S:278 E:289 ||| JJ
proteins  ||| S:289 E:298 ||| NNS
with  ||| S:298 E:303 ||| IN
a  ||| S:303 E:305 ||| DT
BoNTA  ||| S:305 E:311 ||| JJ
complex  ||| S:311 E:319 ||| NN
( ||| S:319 E:320 ||| -LRB-
BTXCo ||| S:320 E:325 ||| NNP
)  ||| S:325 E:327 ||| -RRB-
in  ||| S:327 E:330 ||| IN
the  ||| S:330 E:334 ||| DT
treatment  ||| S:334 E:344 ||| NN
of  ||| S:344 E:347 ||| IN
crow ||| S:347 E:351 ||| NN
's  ||| S:351 E:354 ||| POS
feet ||| S:354 E:358 ||| NNS
.  ||| S:358 E:360 ||| .
Twelve  ||| S:360 E:367 ||| NNP
U  ||| S:367 E:369 ||| NNP
of  ||| S:369 E:372 ||| IN
each  ||| S:372 E:377 ||| DT
product  ||| S:377 E:385 ||| NN
were  ||| S:385 E:390 ||| VBD
compared  ||| S:390 E:399 ||| VBN
in  ||| S:399 E:402 ||| IN
an  ||| S:402 E:405 ||| DT
intra-individual  ||| S:405 E:422 ||| JJ
study  ||| S:422 E:428 ||| NN
in  ||| S:428 E:431 ||| IN
21  ||| S:431 E:434 ||| CD
participants  ||| S:434 E:447 ||| NNS
with  ||| S:447 E:452 ||| IN
a  ||| S:452 E:454 ||| DT
facial  ||| S:454 E:461 ||| JJ
wrinkle  ||| S:461 E:469 ||| NN
scale  ||| S:469 E:475 ||| NN
( ||| S:475 E:476 ||| -LRB-
FWS ||| S:476 E:479 ||| NNP
)  ||| S:479 E:481 ||| -RRB-
score  ||| S:481 E:487 ||| NN
of  ||| S:487 E:490 ||| IN
2  ||| S:490 E:492 ||| CD
to  ||| S:492 E:495 ||| TO
3 ||| S:495 E:496 ||| CD
.  ||| S:496 E:498 ||| .
Evaluations  ||| S:498 E:510 ||| NNS
were  ||| S:510 E:515 ||| VBD
done  ||| S:515 E:520 ||| VBN
for  ||| S:520 E:524 ||| IN
up  ||| S:524 E:527 ||| RB
to  ||| S:527 E:530 ||| TO
4  ||| S:530 E:532 ||| CD
months ||| S:532 E:538 ||| NNS
.  ||| S:538 E:540 ||| .
Subjects  ||| S:540 E:549 ||| NNS
with  ||| S:549 E:554 ||| IN
an  ||| S:554 E:557 ||| DT
improvement  ||| S:557 E:569 ||| NN
of  ||| S:569 E:572 ||| IN
at  ||| S:572 E:575 ||| IN
least  ||| S:575 E:581 ||| JJS
1  ||| S:581 E:583 ||| CD
point  ||| S:583 E:589 ||| NN
on  ||| S:589 E:592 ||| IN
the  ||| S:592 E:596 ||| DT
FWS  ||| S:596 E:600 ||| NNP
were  ||| S:600 E:605 ||| VBD
considered  ||| S:605 E:616 ||| VBN
responders ||| S:616 E:626 ||| NN
.  ||| S:626 E:628 ||| .
One  ||| S:628 E:632 ||| CD
month  ||| S:632 E:638 ||| NN
after  ||| S:638 E:644 ||| IN
treatment ||| S:644 E:653 ||| NN
,  ||| S:653 E:655 ||| ,
the  ||| S:655 E:659 ||| DT
percentage  ||| S:659 E:670 ||| NN
of  ||| S:670 E:673 ||| IN
responders  ||| S:673 E:684 ||| NN
was  ||| S:684 E:688 ||| VBD
slightly  ||| S:688 E:697 ||| RB
higher  ||| S:697 E:704 ||| JJR
for  ||| S:704 E:708 ||| IN
the  ||| S:708 E:712 ||| DT
BoNTA  ||| S:712 E:718 ||| JJ
side  ||| S:718 E:723 ||| NN
( ||| S:723 E:724 ||| -LRB-
95 ||| S:724 E:726 ||| CD
% ||| S:726 E:727 ||| NN
)  ||| S:727 E:729 ||| -RRB-
than  ||| S:729 E:734 ||| IN
the  ||| S:734 E:738 ||| DT
BTXCo  ||| S:738 E:744 ||| JJ
side  ||| S:744 E:749 ||| NN
( ||| S:749 E:750 ||| -LRB-
90 ||| S:750 E:752 ||| CD
% ||| S:752 E:753 ||| NN
) ||| S:753 E:754 ||| -RRB-
.  ||| S:754 E:756 ||| .
After  ||| S:756 E:762 ||| IN
4  ||| S:762 E:764 ||| CD
months ||| S:764 E:770 ||| NNS
,  ||| S:770 E:772 ||| ,
both  ||| S:772 E:777 ||| DT
sides  ||| S:777 E:783 ||| NNS
still  ||| S:783 E:789 ||| RB
showed  ||| S:789 E:796 ||| VBD
good  ||| S:796 E:801 ||| JJ
efficacy ||| S:801 E:809 ||| NN
,  ||| S:809 E:811 ||| ,
with  ||| S:811 E:816 ||| IN
an  ||| S:816 E:819 ||| DT
84 ||| S:819 E:821 ||| CD
%  ||| S:821 E:823 ||| NN
response  ||| S:823 E:832 ||| NN
rate  ||| S:832 E:837 ||| NN
and  ||| S:837 E:841 ||| CC
greater  ||| S:841 E:849 ||| JJR
than  ||| S:849 E:854 ||| IN
30 ||| S:854 E:856 ||| CD
%  ||| S:856 E:858 ||| NN
FWS  ||| S:858 E:862 ||| NNP
reduction  ||| S:862 E:872 ||| NN
( ||| S:872 E:873 ||| -LRB-
no  ||| S:873 E:876 ||| DT
statistically  ||| S:876 E:890 ||| JJ
significant  ||| S:890 E:902 ||| JJ
difference  ||| S:902 E:913 ||| NN
between  ||| S:913 E:921 ||| IN
the  ||| S:921 E:925 ||| DT
products ||| S:925 E:933 ||| NNS
) ||| S:933 E:934 ||| -RRB-
.  ||| S:934 E:936 ||| .
After  ||| S:936 E:942 ||| IN
1  ||| S:942 E:944 ||| CD
month ||| S:944 E:949 ||| NN
,  ||| S:949 E:951 ||| ,
FWS  ||| S:951 E:955 ||| NNP
score  ||| S:955 E:961 ||| NN
at  ||| S:961 E:964 ||| IN
rest  ||| S:964 E:969 ||| NN
was  ||| S:969 E:973 ||| VBD
approximately  ||| S:973 E:987 ||| RB
66 ||| S:987 E:989 ||| CD
%  ||| S:989 E:991 ||| NN
lower  ||| S:991 E:997 ||| JJR
for  ||| S:997 E:1001 ||| IN
BoNTA ||| S:1001 E:1006 ||| NNP
,  ||| S:1006 E:1008 ||| ,
versus  ||| S:1008 E:1015 ||| CC
63 ||| S:1015 E:1017 ||| CD
%  ||| S:1017 E:1019 ||| NN
lower  ||| S:1019 E:1025 ||| JJR
for  ||| S:1025 E:1029 ||| IN
BTXCo ||| S:1029 E:1034 ||| JJ
.  ||| S:1034 E:1036 ||| .
After  ||| S:1036 E:1042 ||| IN
4  ||| S:1042 E:1044 ||| CD
months ||| S:1044 E:1050 ||| NNS
,  ||| S:1050 E:1052 ||| ,
FWS  ||| S:1052 E:1056 ||| NNP
reduction  ||| S:1056 E:1066 ||| NN
was  ||| S:1066 E:1070 ||| VBD
approximately  ||| S:1070 E:1084 ||| RB
50 ||| S:1084 E:1086 ||| CD
% ||| S:1086 E:1087 ||| NN
.  ||| S:1087 E:1089 ||| .
Both  ||| S:1089 E:1094 ||| DT
botulinum  ||| S:1094 E:1104 ||| JJ
toxin  ||| S:1104 E:1110 ||| NN
A  ||| S:1110 E:1112 ||| DT
products  ||| S:1112 E:1121 ||| NNS
displayed  ||| S:1121 E:1131 ||| VBD
high  ||| S:1131 E:1136 ||| JJ
efficacy  ||| S:1136 E:1145 ||| NN
and  ||| S:1145 E:1149 ||| CC
good  ||| S:1149 E:1154 ||| JJ
tolerability  ||| S:1154 E:1167 ||| NN
at  ||| S:1167 E:1170 ||| IN
a  ||| S:1170 E:1172 ||| DT
dose  ||| S:1172 E:1177 ||| NN
ratio  ||| S:1177 E:1183 ||| NN
of  ||| S:1183 E:1186 ||| IN
1 ||| S:1186 E:1187 ||| CD
: ||| S:1187 E:1188 ||| :
1 ||| S:1188 E:1189 ||| CD
,  ||| S:1189 E:1191 ||| ,
with  ||| S:1191 E:1196 ||| IN
no  ||| S:1196 E:1199 ||| DT
statistically  ||| S:1199 E:1213 ||| JJ
significant  ||| S:1213 E:1225 ||| JJ
differences  ||| S:1225 E:1237 ||| NNS
between  ||| S:1237 E:1245 ||| IN
them ||| S:1245 E:1249 ||| PRP
.  ||| S:1249 E:1251 ||| .
The  ||| S:1251 E:1255 ||| DT
high  ||| S:1255 E:1260 ||| JJ
response  ||| S:1260 E:1269 ||| NN
rates  ||| S:1269 E:1275 ||| NNS
observed  ||| S:1275 E:1284 ||| VBD
after  ||| S:1284 E:1290 ||| IN
4  ||| S:1290 E:1292 ||| CD
months  ||| S:1292 E:1299 ||| NNS
suggest  ||| S:1299 E:1307 ||| VBP
a  ||| S:1307 E:1309 ||| DT
good  ||| S:1309 E:1314 ||| JJ
effectiveness  ||| S:1314 E:1328 ||| NN
beyond  ||| S:1328 E:1335 ||| IN
this  ||| S:1335 E:1340 ||| DT
observation  ||| S:1340 E:1352 ||| JJ
period ||| S:1352 E:1358 ||| NN
.  ||| S:1358 E:1360 ||| .
